ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Amgen To Buy KAI Pharma For $315 Million In Cash

DOW JONES NEWSWIRES Amgen Inc. (AMGN) has agreed to acquire privately held company KAI Pharmaceuticals for $315 million in cash, giving the drug maker rights to an experimental drug to treat chronic kidney disease. In connection with the deal, Amgen is providing a loan prior to closing for Phase 3 clinical testing of KAI-4169, a drug that is being studied for the treatment of secondary hyperparathyroidism, a common complication for patients who are on dialysis. The deal will give Amgen rights to KAI-4169, outside of Japan. "KAI has demonstrated encouraging results in the clinic. We are excited about acquiring KAI, as well as the opportunity to potentially deliver a novel therapy for chronic kidney disease patients on dialysis suffering from secondary hyperparathyroidism," said Sean E. Harper, executive vice president of research and development at Amgen. Amgen, the biggest stand-alone biotechnology company, has been making acquisitions in a bid to bolster its research-and-development pipeline as sales growth for older drugs has slowed. The transaction, which has been approved by KAI stockholders and both companies' boards, is subject to regulatory approvals. After the deal is completed, KAI will become a wholly owned unit of Amgen. Amgen shares closed at $67.02 on Monday and were inactive in premarket trading. The stock is up 4.4% so far this year. ---By Kristin Jones, Dow Jones Newswires; 212-416-2208; kristin.jones@dowjones.com

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
03/29/201716:07:00FDA Grants Priority Review For Amgen's BLINCYTO® (blinatumomab...
03/29/201716:03:00Journal Of Clinical Oncology Publishes Data On BLINCYTO® (Blinatumomab...
03/28/201719:06:35Statement of Changes in Beneficial Ownership (4)
03/28/201719:04:45Statement of Changes in Beneficial Ownership (4)
03/28/201719:03:06Statement of Changes in Beneficial Ownership (4)
03/28/201719:00:45Statement of Changes in Beneficial Ownership (4)
03/28/201718:58:56Statement of Changes in Beneficial Ownership (4)
03/28/201718:57:10Statement of Changes in Beneficial Ownership (4)
03/28/201718:55:09Statement of Changes in Beneficial Ownership (4)
03/28/201718:52:54Statement of Changes in Beneficial Ownership (4)
03/28/201709:00:00Amgen Awards Three Golden Tickets for LabCentral Residency
03/23/201716:00:00European Commission Approves AMGEVITA™ (Biosimilar Adalimumab) F...
03/19/201714:00:00Analyses Of PCSK9 Inhibitor Prescription Rejection Rates Demonstrate...
03/18/201708:00:00Lowering LDL Levels With Repatha® (Evolocumab) Did Not Adversely...
03/17/201719:48:00Amgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke...
03/17/201714:05:00Amgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke...
03/17/201714:00:00Amgen's Money-Back Guarantee
03/17/201712:14:00Amgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke...
03/17/201709:29:00Amgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
03/17/201709:00:00Landmark Outcomes Study Shows That Repatha® (Evolocumab) Decreases...

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US